Bethune SJ, Schultheiss N, Henck J-O
Intermediate Protocol For researchers with prior experience using incretin-based peptides who already know their GI tolerance
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 16 GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway Authors Xiang J , Qin L , Zhong J, Xia N , Liang Y Received 12 June 2023 Accepted for publication 5 August 2023 Published 15 August 2023 Volume 2023:16 Pages 24332446 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Konstantinos Tziomalos Jie Xiang, 1 Liyan Qin, 2 Jinling Zhong, 3 Ning Xia, 2 Yuzhen Liang 3 1 Department of Clinical Nutrition, The First Affiliated Hospital of Guangxi Medical University, Nanning, Peoples Republic of China
Commensurate with the prescribing information, 6 treatment was discontinued if liraglutide, 3.0 mg, was not tolerated
Concentration gradient was found to exist as levels of all three markers were significantly lower in the follicular fluid compared with serum levels [15]
weight loss support, cardio vascular support as well as decrease triglycerides
